You are currently viewing the abstract.
View Full TextLog in to view the full text
AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.
More options
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
Lending PD1 a helping hand
LAG3 is an inhibitory receptor expressed on exhausted T cells that is thought to temper T cell activation by engaging peptide–MHC class II complexes. Here, Andrews et al. have engineered mice expressing a noncleavable form of LAG3 (LAG3NC) that cannot be shed from the cell surface by ADAM family proteases. By generating mouse strains that express LAG3NC ion-distinct T cell types, they found that LAG3 shedding by conventional CD4+ T cells rather than T regulatory cells (Tregs) or CD8+ T cells to be important for driving responsiveness to anti-PD1. Although both CD8+ T cells and Tregs have received considerable attention in the context of immunotherapy, this study highlights the importance of T cell help in promoting antitumor immunity.
Abstract
Mechanisms of resistance to cancer immunotherapy remain poorly understood. Lymphocyte activation gene–3 (LAG3) signaling is regulated by a disintegrin and metalloprotease domain-containing protein–10 (ADAM10)– and ADAM17-mediated cell surface shedding. Here, we show that mice expressing a metalloprotease-resistant, noncleavable LAG3 mutant (LAG3NC) are resistant to PD1 blockade and fail to mount an effective antitumor immune response. Expression of LAG3NC intrinsically perturbs CD4+ T conventional cells (Tconvs), limiting their capacity to provide CD8+ T cell help. Furthermore, the translational relevance for these observations is highlighted with an inverse correlation between high LAG3 and low ADAM10 expression on CD4+ Tconvs in the peripheral blood of patients with head and neck squamous cell carcinoma, which corresponded with poor prognosis. This correlation was also observed in a cohort of patients with skin cancers and was associated with increased disease progression after standard-of-care immunotherapy. These data suggest that subtle changes in LAG3 inhibitory receptor signaling can act as a resistance mechanism with a substantive effect on patient responsiveness to immunotherapy.
- Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works
This is an article distributed under the terms of the Science Journals Default License.
